Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
US12059426B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2023 |
| Grant date | Aug 13, 2024 |
| Priority date | — |
| Expiry date | Jul 13, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.